Iron sorbitex
| Code | Size | Price |
|---|
| TAR-T32193-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Iron Sorbitex is used for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease. Iron Sorbitex can be used as an Iron Sorbitex replacement product used for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease.
CAS:
62765-90-6
Formula:
C12H19FeO13
Molecular Weight:
427.116
Purity:
0.98
SMILES:
[Fe+3].OCC(O)C(O)C(O)C(O)CO.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
References
1. Urbach A, Brueckner J, Witte OW. Cortical spreading depolarization stimulates gliogenesis in the rat entorhinal cortex. J Cereb Blood Flow Metab. 2015 Mar 31;35(4):576-82. doi: 10.1038/jcbfm.2014.232. PubMed PMID: 25515215; PubMed Central PMCID: PMC4420877.
2. Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc. 2009 Nov;59(11):764-8. PubMed PMID: 20361676.
3. Galleano M, Lemberg A, Puntarulo S. Does hepatomegaly alter iron-dependent oxidative effects in human plasma? Hum Exp Toxicol. 2003 Jul;22(7):401-5. PubMed PMID: 12929730.
4. Poljak-Blazi M, Kralj M, Hadzija MP, Zarkovi? N, Zarkovi? K, Waeg G. Involvement of lipid peroxidation, oncogene expression and induction of apoptosis in the antitumorous activity of ferric-sorbitol-citrate. Cancer Biother Radiopharm. 2000 Jun;15(3):285-93. PubMed PMID: 10941536.